ACE2 and COVID-19: When assessing the number of counts that align to the non-ACE2 blocking C135 antibody, a SARS-CoV-2-specific NAb, survivors had significantly more (15059.4) than non-survivors (1,412.7, p = 0.016) on Day 0 but not on Day 3, suggesting an initial phase of NAb production may be critical for surviving COVID-19 ICU admission.